Five Prime Therapeutics Announces Oral Presentation of Initial Data From Ongoing Phase 1b Trial of FP-1039/GSK3052230 in Squamous Non Small Cell Lung Cancer and Mesothelioma at World Conference on Lung Cancer
August 24, 2015 at 04:20 AM EDT
Five Prime Therapeutics, Inc. (Nasdaq: FPRX) today announced that initial data from GlaxoSmithKline (NYSE: GSK) ongoing Phase 1b trial ...
